Silver Book Fact

Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.

Watson, Judy J, Shelley J Allen, and David Dawburn. Targeting New Growth Factor in Pain: What is the therapeutic potential?. BioDrugs. 2008; 22(6): 349-59. http://www.mendeley.com/catalog/targeting-nerve-growth-factor-pain-therapeutic-potential/

Reference

Title
Targeting New Growth Factor in Pain: What is the therapeutic potential?
Publication
BioDrugs
Publication Date
2008
Authors
Watson, Judy J, Shelley J Allen, and David Dawburn
Volume & Issue
Volume 22, Issue 6
Pages
349-59
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A meta-analysis of duloxetine, an anti-depressant, found a 50% reduction in pain at 12 weeks for diabetic peripheral neuropathy, and a 50% reduction in pain at 12 weeks for fibromyalgia.  
  • Researchers have discovered that some types of glial cells have a major impact on persistent neuropathic pain and that targeting these cells may result in a new class of disease…  
  • The Mayo Clinic Pain Rehabilitation Center helps people with persistent pain return to an active lifestyle and has found that among patients who finish the program, nearly 84% report greater…  
  • Pain education programs and pain consultations have been found to improve pain (average pain was 31% versus 20%) and daily interference (20% versus 2.5%) in oncology outpatients. Patient adherence…  
  • A biopsychosocial approach (i.e., one that takes into account physical, emotional, and environmental factors in the assessment and treatment of pain) has been found to improve the pain care of…